It’s not always obvious if a horse has PPID, but once the blood work confirms it, PRASCEND tablets helps manage the clinical signs, so horses feel more like themselves again.
Prascend®
(pergolide tablets)
(pergolide tablets)
The most-proven treatment to control the clinical signs associated with PPID in horses.1
DETAILS
PRASCEND – veterinarians’ most trusted treatment
PRASCEND is the most-proven treatment available to control the clinical signs associated with PPID in horses.1 Pituitary pars intermedia dysfunction (PPID), also referred to as equine Cushing’s disease, is one of the most common endocrine disorders in horses. The signs are often subtle, but the disease can be serious.
Horses treated with PRASCEND:
- CONTROLLED SIGNS:
Clinical signs improved within 3 months and continued through 6 months.1 - PROVEN SUCCESS:
Three out of four horses evaluated were considered treatment successes.1 - CLEAR IMPROVEMENT:
Hypertrichosis (delayed shedding) improved in 89% of treated horses within 6 months.1
PRASCEND tablets contain 1 mg pergolide for horses, as pergolide mesylate, a dopamine receptor agonist for oral use in horses only.
FEATURES & BENEFITS
Features
-
Most proven treatment for PPID in horses
-
Contains 1 mg pergolide for horses, as pergolide mesylate, a dopamine receptor agonist
-
Single-scored tablets make it simple to adjust dosage
Benefits
-
Improved clinical signs within 3 months and continued through 6 months1
-
Three out of four horses evaluated were considered treatment successes1
-
Hypertrichosis (delayed shedding) improved in 89% of treated horses within 6 months1
DOSAGE & ADMINISTRATION
Prascend® (pergolide tablets) is available with a prescription by a veterinarian, but can be administered by a horse owner. Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily.
PRASCEND tablets should not be crushed due to the potential for increased human exposure, and care should be taken to minimize exposure when splitting tablets.
For more information, please read the PRASCEND Product Insert.
RESOURCES
SAFETY
Storage: Store at or below 25°C (77°F).
IMPORTANT SAFETY INFORMATION: PRASCEND is for use in horses only. PRASCEND has not been evaluated in breeding, pregnant, or lactating horses. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. If severe, a temporary dose reduction may be necessary. Weight loss, lack of energy, and behavioral changes also may be observed. PRASCEND is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Not for use in humans. Do not ingest the product. PRASCEND tablets should not be crushed due to the potential for increased human exposure. Pergolide, like other ergot derivatives, may cause emesis, dizziness, lethargy or low blood pressure. Pregnant or lactating women should wear gloves when administering this product. Store this product separately away from human medicinal products and handle this product with care to avoid accidental ingestion. Keep PRASCEND in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eaten PRASCEND tablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingest PRASCEND tablets. Refer to the package insert for complete product information.
References
1PRASCEND [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Animal Health USA Inc.; 2024
Trademarks
PRASCEND® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-EQU-0125-2021-V2